Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

677
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
677
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

1.1K
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

681
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
681
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

524
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
524
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

1.3K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.3K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

396
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.

Kidney international reports·2026
Same author

Perivascular fat, hypertension, and cardiovascular disease.

Kidney international·2026
Same author

French nephrologists’ practices in the management of anemia and iron deficiency in chronic kidney disease

Nephrologie & therapeutique·2026
Same author

Mechanism of reduced intestinal phosphate absorption by tenapanor: a hypothesis.

Clinical kidney journal·2026
Same author

Contribution of genetic variants to nephrolithiasis.

Kidney international·2025
Same author

A longitudinal analysis of haemoglobin levels and major cardiovascular events.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025

Related Experiment Video

Updated: Apr 27, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

1.8K

Calcimimetics and outcomes in CKD.

Tilman B Drüeke1

  • 1Inserm Unit 1088, UFR de Médecine/Pharmacie, Picardy University Jules Verne , Amiens, France.

Kidney International Supplements
|July 17, 2014
PubMed
Summary

Calcimimetics show promise in inhibiting vascular calcification and arterial remodeling in chronic kidney disease (CKD) models. Clinical trials suggest potential cardiovascular benefits, warranting further investigation.

Area of Science:

  • Nephrology and Cardiovascular Medicine
  • Pharmacology

Background:

  • Experimental studies indicate calcimimetics inhibit vascular calcification and arterial remodeling in chronic kidney disease (CKD) models.
  • The calcium-sensing receptor (CaR) is expressed in vascular tissue, suggesting a direct role for calcimimetics beyond secondary hyperparathyroidism control.

Approach:

  • Review of experimental data and clinical trials (ADVANCE, EVOLVE) evaluating calcimimetics in CKD patients.
  • Analysis of cinacalcet's effects on vascular calcification and cardiovascular outcomes in CKD stage 5D.

Key Points:

  • Calcimimetics demonstrated inhibitory effects on vascular calcification and arterial remodeling in animal models of CKD.
  • Clinical trials ADVANCE and EVOLVE did not meet primary endpoints by intent-to-treat analysis.
  • Prespecified analyses in clinical trials suggested potential cardiovascular risk reduction, aligning with experimental findings.
Keywords:
CKDCKD-MBDcalcimimeticsoutcomesvascular calcification

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry
10:24

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry

Published on: October 28, 2014

14.9K

Related Experiment Videos

Last Updated: Apr 27, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

1.8K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry
10:24

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry

Published on: October 28, 2014

14.9K

Conclusions:

  • While primary endpoints were missed, experimental and secondary analyses suggest calcimimetics may offer cardiovascular benefits in CKD patients.
  • Further clinical trials are necessary to definitively establish the role of calcimimetics in managing cardiovascular complications in CKD.